Meloxicam Tablet
Product Images NDC 11788-098

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Meloxicam (NDC 11788-098). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aiping Pharmaceutical, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Container-label-15mg (Container 15mg 1000s)

Meloxicam Tablets USP 15 mg oral tablets in a 1000 count container label. The label includes NDC 11788-047-10, pharmacist dispensing instructions, storage conditions between 20°C to 25°C, and manufacturer information for AiPing Pharmaceutical, Inc. and A&Z Pharmaceutical, Inc. The label also shows Rx only and the bottle size as 500 cc.*

FDA Label Image

Container-label-7.5mg (Container 7.5mg 1000s)

Meloxicam Tablets USP 7.5 mg label for a 1000-count bottle with a 500 cc size. The label includes the NDC 11788-046-10, states the drug is for oral use, and is manufactured for AiPing Pharmaceutical, Inc. It instructs to dispense with medication guide and store at 20°C to 25°C. The package is marked Rx only.*

FDA Label Image

Mg1 (Mg1)

This image shows a text excerpt from a drug information panel discussing precautions related to the use of NSAIDs (nonsteroidal anti-inflammatory drugs). It highlights warnings about not taking NSAIDs before or after coronary artery bypass graft surgery (CABG) and advises avoiding NSAIDs after a recent heart attack unless directed by a healthcare provider, due to an increased risk of another heart attack.*

FDA Label Image

Mg2 (Mg2)

A text panel listing risk factors that increase the likelihood of ulcers or bleeding during use of NSAIDs. Factors include history of ulcers, corticosteroid or anticoagulant use, high NSAID doses, age, smoking, alcohol use, health status, liver disease, and bleeding problems.*

FDA Label Image

Mg3 (Mg3)

Meloxicam 15 mg oral tablets in a blister pack. The silver foil backing is printed with black text including the product name, strength, and other manufacturing information. Each tablet is round and white. The labeler is AiPing Pharmaceutical, Inc.*

FDA Label Image

Mg4 (Mg4)

Drug Facts text panel for Meloxicam tablets includes warnings about serious side effects such as stroke, heart attack, shortness of breath, chest pain, weakness, slurred speech, and swelling of the face or throat. The text emphasizes caution in use and indicates these are important health warnings.*

FDA Label Image

Mg5 (Mg5)

A partial text panel listing potential side effects of a medication, including symptoms like nausea, diarrhea, yellowing skin or eyes, vomiting blood, unusual weight gain, and swelling. The text is bulleted and appears to be part of a larger drug safety or side effects section.*

FDA Label Image

Structural (Structural Formula)

Chemical structure of Meloxicam, showing its molecular arrangement with a sulfonamide group, hydroxyl group, and thiazole ring, corresponding to the active ingredient in MELOXICAM tablets by AiPing Pharmaceutical, Inc.*

FDA Label Image

Table 1a (Table 1a)

Table presenting adverse event percentages occurring in 2% or more of Meloxicam patients during a 12-week osteoarthritis placebo- and active-controlled trial. It compares events for placebo, Meloxicam 7.5 mg daily, Meloxicam 15 mg daily, and Diclofenac 100 mg daily across categories including gastrointestinal, body as a whole, central and peripheral nervous system, respiratory, and skin events.*

FDA Label Image

Table 1b (Table 1b)

A data table presenting adverse events occurring in 2% or more of patients taking Meloxicam in two 12-week rheumatoid arthritis placebo-controlled trials. It compares the percentage of patients experiencing various side effects across three groups: placebo, 7.5 mg daily Meloxicam, and 15 mg daily Meloxicam. Categories include gastrointestinal disorders, general disorders and administration site conditions, infections, musculoskeletal disorders, nervous system disorders, and skin/subcutaneous tissue disorders.*

FDA Label Image

Table 2.1 (Table 2.1)

A data table listing adverse reactions and side effects by body system for the drug Meloxicam. Categories include Body as a Whole, Cardiovascular, Central and Peripheral Nervous System, Gastrointestinal, Heart Rate and Rhythm, Hematologic, Liver and Biliary System, Metabolic and Nutritional, Psychiatric, Respiratory, Skin and Appendages, Special Senses, and Urinary System, with associated symptoms and conditions noted.*

FDA Label Image

Table 2 (Table 2)

A data table showing adverse events occurring in 2% or more of Meloxicam patients during 4 to 6 weeks and 6 months active-controlled osteoarthritis trials. It compares incidences at Meloxicam 7.5 mg and 15 mg daily doses across categories such as gastrointestinal, body as a whole, central and peripheral nervous system, hematologic, musculoskeletal, psychiatric, respiratory, skin, and urinary events.*

FDA Label Image

Table 3.1 (Table 3.1)

Text panel listing drug interaction information for meloxicam, covering clinical impacts and interventions when used concomitantly with lithium, methotrexate, cyclosporine, NSAIDs and salicylates, and pemetrexed. It details risks such as toxicity, changes in renal function, and recommendations for monitoring or avoiding combined use.*

FDA Label Image

Table 3 (Table 3)

Data table titled 'Clinically Significant Drug Interactions with Meloxicam' presenting drugs that interfere with hemostasis, aspirin, ACE inhibitors, angiotensin receptor blockers, beta-blockers, and diuretics. The table summarizes clinical impacts and recommended interventions for each drug interaction category.*

FDA Label Image

Image Description (Table 4)

A pharmacokinetic data table titled 'Table 4 Single Dose and Steady-State Pharmacokinetic Parameters for Oral 7.5 mg and 15 mg Meloxicam'. It presents mean and % coefficient of variation (%CV) values for parameters including Cmax, tmax, t1/2, CL/f, and Vz/f across different populations: healthy male adults, elderly males and females, renal failure (fasted), and hepatic insufficiency (fasted). The table distinguishes between 7.5 mg and 15 mg tablet or capsule forms.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.